Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Degarelix
Drug ID BADD_D00599
Description Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
Indications and Usage Degaralix is used for the management of advanced prostate cancer.
Marketing Status approved
ATC Code L02BX02
DrugBank ID DB06699
KEGG ID D08901
MeSH ID C431566
PubChem ID 16136245
TTD Drug ID D0Y7KH
NDC Product Code 55566-8403; 59651-477; 55566-8303
UNII SX0XJI3A11
Synonyms acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide | uglypeptide1 | Ac-2Nal-4Cpa-3Pal-Ser-4Aph(hydroorotyl)-4Aph(carbamoyl)-Leu-ILys-pro-Ala-NH2 | Firmagon | degarelix | degarelix acetate | Gonax | FE 200486 | FE200486 | FE-200486
Chemical Information
Molecular Formula C82H103ClN18O16
CAS Registry Number 214766-78-6
SMILES CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CC2=CC=C(C=C2)NC (=O)N)NC(=O)C(CC3=CC=C(C=C3)NC(=O)C4CC(=O)NC(=O)N4)NC(=O)C(CO)NC(=O)C(CC5=CN=CC= C5)NC(=O)C(CC6=CC=C(C=C6)Cl)NC(=O)C(CC7=CC8=CC=CC=C8C=C7)NC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gynaecomastia21.05.04.003; 05.05.02.003--
Haematochezia07.12.02.003; 24.07.02.012--Not Available
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypersomnia19.02.05.001; 17.15.01.001--
Hypertension24.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Incontinence17.05.01.006; 07.01.06.011; 20.02.02.004--Not Available
Influenza like illness08.01.03.010--
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.042--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site haemorrhage24.07.01.010; 12.07.03.005; 08.02.03.005--Not Available
Injection site hypersensitivity12.07.03.006; 10.01.03.017; 08.02.03.006--Not Available
Injection site induration12.07.03.007; 08.02.03.007--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site mass12.07.03.010; 08.02.03.009--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site pruritus08.02.03.013; 23.03.12.007; 12.07.03.014--Not Available
Injection site rash23.03.13.010; 12.07.03.032; 08.02.03.032--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injection site urticaria08.02.03.029; 23.04.02.003; 12.07.03.029; 10.01.06.003--Not Available
Injection site warmth12.07.03.036; 08.02.03.036--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Joint swelling15.01.02.004--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages